Clinical Trial Update: An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating two dose levels of certolizumab pegol for plaque psoriasis; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Biopharma S.P.R.L. | Conditions: Psoriasis, Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2018-08-13